https://www.statnews.com/2023/05/24/fda-delays-decision-on-sareptas-gene-therapy-for-duchenne-muscular-dystrophy/
0
0
FDA delays decision on Sarepta's gene therapy for Duchenne - STAT
5/24/23 at 5:48am
Organization
STAT
Authors
Adam Feuerstein Jason Mast
Details
39 words
Summarize
Business & Industrial Health delays decision FDA Sarepta Duchenne - STAT
The FDA is delaying by one month a decision on the approval of a gene therapy for Duchenne muscular dystrophy, the treatment’s maker, Sarepta Therapeutics, said Wednesday.
Create an account or login to join the discussion